BNP PARIBAS ASSET MANAGEMENT Holding S.A. Sells 25,094 Shares of DexCom, Inc. $DXCM

BNP PARIBAS ASSET MANAGEMENT Holding S.A. lessened its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 7.4% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 314,968 shares of the medical device company’s stock after selling 25,094 shares during the quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. owned approximately 0.08% of DexCom worth $21,188,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the company. Andra AP fonden purchased a new position in shares of DexCom in the second quarter worth $26,000. Twin Peaks Wealth Advisors LLC acquired a new stake in shares of DexCom in the second quarter worth $26,000. SJS Investment Consulting Inc. raised its holdings in shares of DexCom by 4,800.0% during the third quarter. SJS Investment Consulting Inc. now owns 392 shares of the medical device company’s stock worth $26,000 after purchasing an additional 384 shares during the last quarter. Financial Consulate Inc. purchased a new position in shares of DexCom during the third quarter worth $29,000. Finally, Migdal Insurance & Financial Holdings Ltd. acquired a new position in DexCom during the second quarter valued at $45,000. Hedge funds and other institutional investors own 97.75% of the company’s stock.

DexCom Stock Performance

NASDAQ DXCM opened at $72.27 on Friday. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.88 and a quick ratio of 1.59. The company has a market cap of $27.81 billion, a P/E ratio of 34.41, a P/E/G ratio of 1.42 and a beta of 1.49. The stock has a 50-day moving average of $69.37 and a two-hundred day moving average of $69.37. DexCom, Inc. has a 1-year low of $54.11 and a 1-year high of $91.87.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings data on Thursday, February 12th. The medical device company reported $0.68 EPS for the quarter, beating the consensus estimate of $0.65 by $0.03. The business had revenue of $1.26 billion during the quarter, compared to analyst estimates of $1.25 billion. DexCom had a net margin of 17.94% and a return on equity of 32.12%. The business’s revenue for the quarter was up 13.1% compared to the same quarter last year. During the same quarter last year, the firm posted $0.45 earnings per share. As a group, analysts anticipate that DexCom, Inc. will post 2.03 EPS for the current year.

Analysts Set New Price Targets

Several analysts have commented on DXCM shares. Wall Street Zen lowered DexCom from a “strong-buy” rating to a “buy” rating in a report on Sunday, November 16th. Mizuho upped their target price on DexCom from $78.00 to $90.00 and gave the company an “outperform” rating in a report on Friday, February 13th. Sanford C. Bernstein reiterated an “outperform” rating and set a $86.00 price target (up previously from $84.00) on shares of DexCom in a report on Friday, January 9th. JPMorgan Chase & Co. lowered their price target on shares of DexCom from $90.00 to $75.00 and set a “neutral” rating on the stock in a research report on Friday, October 31st. Finally, Robert W. Baird set a $87.00 target price on shares of DexCom in a research note on Friday, February 13th. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $85.18.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.